Skip to content
2000
Volume 13, Issue 33
  • ISSN: 1381-6128
  • E-ISSN: 1873-4286

Abstract

The short chain fatty acid valproic acid (VPA, 2-propylpetanoic acid) is approved for the treatment of epilepsia, bipolar disorders and migraine and clinically used for schizophrenia. In 1999, the first clinical anti-cancer trial using VPA was initiated. Currently, VPA is examined in numerous clinical trials for different leukaemias and solid tumour entities. In addition to clinical assessment, the experimental examination of VPA as anti-cancer drug is ongoing and many questions remain unanswered. Although other mechanisms may also contribute to VPA-induced anti-cancer effects, inhibition of histone deacetylases appears to play a central role. This review focuses on recent developments regarding the anti-cancer activity of VPA.

Loading

Article metrics loading...

/content/journals/cpd/10.2174/138161207782360528
2007-11-01
2025-05-31
Loading full text...

Full text loading...

/content/journals/cpd/10.2174/138161207782360528
Loading

  • Article Type:
    Research Article
Keyword(s): angiogenesis; clinical studies; combination therapy; differentiation; HDAC; Valproic acid
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test